Emergent Stock Based Compensation vs Capital Expenditures Analysis

EBS Stock

USD 10.11 0.08 0.80%

Emergent Biosolutions financial indicator trend analysis is much more than just examining Emergent Biosolutions latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Emergent Biosolutions is a good investment. Please check the relationship between Emergent Biosolutions Stock Based Compensation and its Capital Expenditures accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Emergent Biosolutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.

Stock Based Compensation vs Capital Expenditures

Stock Based Compensation vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Emergent Biosolutions Stock Based Compensation account and Capital Expenditures. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Emergent Biosolutions' Stock Based Compensation and Capital Expenditures is 0.84. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Emergent Biosolutions, assuming nothing else is changed. The correlation between historical values of Emergent Biosolutions' Stock Based Compensation and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Emergent Biosolutions are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Stock Based Compensation i.e., Emergent Biosolutions' Stock Based Compensation and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

0.84

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Capital Expenditures

Capital Expenditures are funds used by Emergent Biosolutions to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Emergent Biosolutions operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most indicators from Emergent Biosolutions' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Emergent Biosolutions current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Emergent Biosolutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.At this time, Emergent Biosolutions' Selling General Administrative is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 8.8 M in 2024, whereas Tax Provision is likely to drop slightly above 48.4 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	640.9M	593.2M	1.0B	1.1B
Cost Of Revenue	757.5M	693.7M	705.4M	740.7M

Total Operating Expenses Cost Of Revenue

Emergent Biosolutions fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.88	0.51	0.55	0.95	0.74	0.65	0.51	0.6	0.74	0.74	0.43	0.44	0.74	0.62	0.65	0.77	0.58	0.63	0.77	0.73	0.92	0.64	0.42	0.7	0.69
Short Long Term Debt Total	0.88		0.51	0.81	0.73	0.67	0.89	0.27	0.59	0.6	0.73	0.73	0.37	0.6	0.52	0.7	0.6	0.54	0.77	0.7	0.67	0.99	0.59	0.7	0.75	0.71
Other Current Liab	0.51	0.51		0.59	0.39	0.82	0.37	0.69	0.9	0.46	0.79	0.59	-0.39	0.46	0.63	0.75	0.0	0.72	0.79	0.88	-0.05	0.54	0.91	0.3	0.71	0.77
Total Current Liabilities	0.55	0.81	0.59		0.37	0.63	0.74	0.23	0.56	0.46	0.62	0.91	0.03	0.46	0.25	0.56	0.16	0.31	0.79	0.61	0.28	0.73	0.61	0.94	0.6	0.61
Total Stockholder Equity	0.95	0.73	0.39	0.37		0.67	0.43	0.55	0.44	0.8	0.58	0.22	0.53	0.8	0.53	0.46	0.82	0.44	0.49	0.69	0.77	0.79	0.55	0.26	0.51	0.49
Property Plant And Equipment Net	0.74	0.67	0.82	0.63	0.67		0.47	0.84	0.84	0.61	0.92	0.52	-0.23	0.61	0.74	0.79	0.27	0.77	0.81	0.83	0.16	0.69	0.96	0.39	0.81	0.79
Net Debt	0.65	0.89	0.37	0.74	0.43	0.47		-0.03	0.51	0.17	0.65	0.76	0.24	0.17	0.53	0.72	0.4	0.53	0.74	0.45	0.54	0.87	0.38	0.64	0.77	0.73
Retained Earnings	0.51	0.27	0.69	0.23	0.55	0.84	-0.03		0.65	0.61	0.69	0.09	-0.34	0.61	0.55	0.48	0.08	0.62	0.42	0.67	-0.11	0.32	0.83	0.01	0.5	0.47
Accounts Payable	0.6	0.59	0.9	0.56	0.44	0.84	0.51	0.65		0.36	0.91	0.65	-0.37	0.36	0.8	0.92	0.12	0.87	0.86	0.86	0.05	0.63	0.91	0.25	0.87	0.92
Cash	0.74	0.6	0.46	0.46	0.8	0.61	0.17	0.61	0.36		0.41	0.27	0.39	1.0	0.17	0.21	0.56	0.23	0.38	0.72	0.49	0.61	0.59	0.39	0.25	0.23
Non Current Assets Total	0.74	0.73	0.79	0.62	0.58	0.92	0.65	0.69	0.91	0.41		0.6	-0.25	0.41	0.84	0.94	0.24	0.9	0.84	0.78	0.17	0.76	0.89	0.36	0.97	0.93
Non Currrent Assets Other	0.43	0.73	0.59	0.91	0.22	0.52	0.76	0.09	0.65	0.27	0.6		-0.09	0.27	0.32	0.65	0.05	0.4	0.85	0.58	0.22	0.68	0.57	0.78	0.63	0.67
Other Assets	0.44	0.37	-0.39	0.03	0.53	-0.23	0.24	-0.34	-0.37	0.39	-0.25	-0.09		0.39	-0.21	-0.26	0.77	-0.34	-0.16	-0.01	0.88	0.38	-0.35	0.19	-0.2	-0.2
Cash And Short Term Investments	0.74	0.6	0.46	0.46	0.8	0.61	0.17	0.61	0.36	1.0	0.41	0.27	0.39		0.17	0.21	0.56	0.23	0.38	0.72	0.49	0.61	0.59	0.39	0.25	0.23
Net Receivables	0.62	0.52	0.63	0.25	0.53	0.74	0.53	0.55	0.8	0.17	0.84	0.32	-0.21	0.17		0.88	0.33	0.91	0.7	0.59	0.22	0.6	0.7	-0.04	0.85	0.85
Good Will	0.65	0.7	0.75	0.56	0.46	0.79	0.72	0.48	0.92	0.21	0.94	0.65	-0.26	0.21	0.88		0.23	0.93	0.86	0.73	0.19	0.74	0.79	0.28	0.98	0.98
Common Stock Shares Outstanding	0.77	0.6	0.0	0.16	0.82	0.27	0.4	0.08	0.12	0.56	0.24	0.05	0.77	0.56	0.33	0.23		0.17	0.23	0.39	0.9	0.64	0.15	0.16	0.24	0.27
Non Current Liabilities Total	0.58	0.54	0.72	0.31	0.44	0.77	0.53	0.62	0.87	0.23	0.9	0.4	-0.34	0.23	0.91	0.93	0.17		0.71	0.67	0.06	0.61	0.78	0.0	0.91	0.86
Inventory	0.63	0.77	0.79	0.79	0.49	0.81	0.74	0.42	0.86	0.38	0.84	0.85	-0.16	0.38	0.7	0.86	0.23	0.71		0.8	0.28	0.78	0.82	0.55	0.84	0.87
Other Current Assets	0.77	0.7	0.88	0.61	0.69	0.83	0.45	0.67	0.86	0.72	0.78	0.58	-0.01	0.72	0.59	0.73	0.39	0.67	0.8		0.32	0.74	0.89	0.37	0.7	0.76
Other Stockholder Equity	0.73	0.67	-0.05	0.28	0.77	0.16	0.54	-0.11	0.05	0.49	0.17	0.22	0.88	0.49	0.22	0.19	0.9	0.06	0.28	0.32		0.7	0.03	0.3	0.23	0.23
Total Liab	0.92	0.99	0.54	0.73	0.79	0.69	0.87	0.32	0.63	0.61	0.76	0.68	0.38	0.61	0.6	0.74	0.64	0.61	0.78	0.74	0.7		0.61	0.59	0.78	0.74
Total Current Assets	0.64	0.59	0.91	0.61	0.55	0.96	0.38	0.83	0.91	0.59	0.89	0.57	-0.35	0.59	0.7	0.79	0.15	0.78	0.82	0.89	0.03	0.61		0.34	0.76	0.79
Short Term Debt	0.42	0.7	0.3	0.94	0.26	0.39	0.64	0.01	0.25	0.39	0.36	0.78	0.19	0.39	-0.04	0.28	0.16	0.0	0.55	0.37	0.3	0.59	0.34		0.35	0.35
Intangible Assets	0.7	0.75	0.71	0.6	0.51	0.81	0.77	0.5	0.87	0.25	0.97	0.63	-0.2	0.25	0.85	0.98	0.24	0.91	0.84	0.7	0.23	0.78	0.76	0.35		0.96
Common Stock	0.69	0.71	0.77	0.61	0.49	0.79	0.73	0.47	0.92	0.23	0.93	0.67	-0.2	0.23	0.85	0.98	0.27	0.86	0.87	0.76	0.23	0.74	0.79	0.35	0.96

Click cells to compare fundamentals

Emergent Biosolutions Account Relationship Matchups

Emergent Biosolutions fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.3B	2.9B	3.0B	3.2B	1.8B	1.2B
Short Long Term Debt Total	811.3M	874.8M	841M	1.4B	860.2M	903.2M
Total Stockholder Equity	1.1B	1.4B	1.6B	1.4B	649.3M	621.9M
Net Debt	643.5M	253.5M	264.9M	763.2M	748.5M	785.9M
Cash	167.8M	621.3M	576.1M	642.6M	111.7M	217.0M
Other Assets	65.6M	115M	57.3M	191.3M	220.0M	231.0M
Cash And Short Term Investments	167.8M	621.3M	576.1M	642.6M	111.7M	217.2M
Common Stock Shares Outstanding	52.4M	53.8M	54.1M	50.1M	51.2M	41.4M
Liabilities And Stockholders Equity	2.3B	2.9B	3.0B	3.2B	1.8B	1.2B
Other Current Assets	20.6M	73.2M	70.4M	57.9M	47.9M	25.8M
Other Stockholder Equity	676.5M	745.3M	677.2M	645.8M	676.7M	710.5M
Total Liab	1.2B	1.4B	1.3B	1.8B	1.2B	1.2B
Other Liab	199.9M	210.7M	156.8M	90.4M	104.0M	66.7M
Current Deferred Revenue	101.9M	131.5M	140.4M	26.4M	30.4M	28.1M
Long Term Debt	798.4M	841M	809.4M	448.5M	446.5M	290.2M
Property Plant And Equipment Gross	542.3M	644.1M	800.1M	817.6M	794.2M	833.9M
Accumulated Other Comprehensive Income	(9.9M)	(25.3M)	(16.1M)	3.1M	(5.7M)	(6.0M)
Property Plant Equipment	542.3M	644.1M	800.1M	817.6M	940.2M	987.3M
Retained Earnings Total Equity	421.8M	726.9M	957.8M	734M	844.1M	440.2M
Deferred Long Term Liab	63.9M	53.2M	94.9M	71.8M	82.6M	86.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Emergent Stock Analysis

When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC